A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity

ClinicalTrials.gov ID: NCT06782490

Public ClinicalTrials.gov record NCT06782490. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced May 8, 2026, 3:55 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2, Randomized, Double-Blind, Four-Arm, Placebo-Controlled, Multicenter Study Assessing the Efficacy, Safety and Tolerability of Three Doses of Orally Administered BMS-986368, a FAAH/MAGL Inhibitor, for the Treatment of Spasticity in Participants With Multiple Sclerosis (BALANCE-MSS-1)

Study identification

NCT ID: NCT06782490
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 2
Lead sponsor: Celgene; Industry
Enrollment: 200 participants

Conditions and interventions

Conditions

Multiple Sclerosis Spasticity

Interventions

BMS-986368 Drug
Placebo Drug

Drug

Eligibility (public fields only)

Age range: 18 Years to 70 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jun 4, 2025
Primary completion: May 25, 2027
Completion: Jun 8, 2027
Last update posted: May 6, 2026

2025 – 2027

United States locations

U.S. sites: 15
U.S. states: 12
U.S. cities: 14

Facility	City	State	ZIP	Site status
Alabama Neurology Associates	Birmingham	Alabama	35209	Recruiting
Perseverance Research Center,LLC	Scottsdale	Arizona	85253	Recruiting
Local Institution - 0017	Aurora	Colorado	80045	Withdrawn
Aqualane Clinical Research	Naples	Florida	34105	Recruiting
USF Health	Tampa	Florida	33612	Recruiting
University of Kansas Medical Center	Kansas City	Kansas	66160	Recruiting
Neurology Center of New England	Foxborough	Massachusetts	02035	Recruiting
Local Institution - 0071	Southfield	Michigan	48034	Not yet recruiting
Washington University School of Medicine	St Louis	Missouri	63110	Recruiting
University of Cincinnati Medical Center	Cincinnati	Ohio	45219	Recruiting
Local Institution - 0039	Columbus	Ohio	43214	Not yet recruiting
Local Institution - 0069	Columbus	Ohio	43235	Withdrawn
Local Institution - 0067	Philadelphia	Pennsylvania	19107	Not yet recruiting
Hope Neurology	Knoxville	Tennessee	37922	Recruiting
EvergreenHealth Medical Center	Kirkland	Washington	98034	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 39 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT06782490, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted May 6, 2026 · Synced May 8, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06782490 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →